Nagai et al. [1] reviewed in this journal the clinicohistopathologic spectrum and classification of idiopathic interstitial pneumonias (IIPs) and summarized the advances in prognosis and treatment. IIPs are defined in histopathologic terms as an intralobular, nongranulomatous inflammatory and fibrotic disorder of the lung basically involving alveolar walls [2••,3•,4•,5,6]. Recently, seven entities were reclassified on the basis of clinical, histopathologic, and imaging features: idiopathic pulmonary fibrosis (IPF), desquamative interstitial pneumonia, respiratory bronchiolitis-associated interstitial lung disease, nonspecific interstitial pneumonia (NSIP), acute interstitial pneumonia, cryptogenic organizing pneumonia, and lymphoid interstitial pneumonia [7•].
To date, diagnostic criteria in the absence of a surgical lung biopsy are available only for IPF [7•,8,9] . IPF is defined as a specific form of chronic fibrosing interstitial pneumonia limited to the lung and associated with the histopathologic appearance of usual interstitial pneumonia (UIP) on surgical biopsy. Improvements of lung function and radiographic features after immunosuppressive treatment using corticosteroids and other drugs (such as azathioprine [10] and cyclophosphamide) are uncommon and the outcome is poor [7•,9,10].
Nonspecific interstitial pneumonia/fibrosis (NSIP) has been defined recently by Katzenstein and Fiorelli [11] . However, the concept of a predominant inflammatory or cellular interstitial pneumonitis was proposed by Carrington et al. [12] and more recently by Poletti and Kitaichi [13] , who termed the histopathologic pattern "unclassified interstitial pneumonia" or "cellular interstitial pneumonia." It is therefore evident that, from the histopathologic point of view, NSIP is not a new pulmonary process. The value of the recent consensus classification was to draw attention to the clinical diseases that have this histopathologic pattern. Previous clinical reports on IPF (or cryptogenic fibrosing alveolitis) must therefore be viewed with caution, because case cohorts may contain a mixed population of IIP, and because of the difficulties (in terms of clinical approach, diagnostic uncertainty, and philosophy) in the differential diagnosis between IPF and NSIP.
Definition and pathology
When attempts are made to stratify patients according to their histologic variant of IIPs, differences in demographic factors, prognosis, and response to therapy be- (Fig. 1) . Cases can be subdivided as cellular NSIP with a predominance of inflammatory changes (Fig. 1A) , mixed NSIP with the presence of both inflammation and fibrosis (Fig. 1B) , and fibrotic NSIP with predominantly fibrosis (Fig. 1C) .
The key features of NSIP are the "temporally uniform" pattern together with a "diffuse interstitial fibrosing process" and the virtual absence of fibroblastic foci and the lack of features of UIP, desquamative interstitial pneu- [15, 23] found that the amount of fibrosis seen on high-resolution CT (HRCT) differed in all groups studied, being greatest in the group with concordant UIP and successively less so in the groups with discordant UIP, fibrotic NSIP, and cellular NSIP, in that order. As Katzenstein and Fiorelli [11] pointed out in their original series, the patients who they studied had markedly variable clinical features and likely represented a heterogeneous population. This has been confirmed by a number of subsequent studies. Further prospective studies are needed to define the clinical, radiologic, and histopathologic features of subsets of NSIP that might allow them to be defined more precisely. Only then might it be possible to attempt to define each entity without recourse to biopsy as in confident HRCT/bronchoalveolar lavage (BAL)-aided diagnoses of IPF.
Prevalence, etiology, and pathogenesis
Because NSIP has existed as a clinical entity for a relatively short period, even less is known about the epidemiology of the disease than the other IIPs. Nonspecific interstitial pneumonia is the most common histopathologic manifestation of toxicity as a result of certain drugs, including amiodarone, nitrofurantoin, gold salts, methotrexate, vincristine, and fludarabine [19] . The prevalence of drug-induced pulmonary toxicity is increasing, and more than 100 drugs are known to cause lung injury [30] . Host factors including genetic polymorphisms may be important determinants of susceptibility to drug adverse effects. Because this lung injury can be progressive and even fatal, early recognition is important to initiate appropriate treatment. Increasingly, a number of idiopathic diseases are being recognized as having significant genetic predisposition.
In this context, a number of single nucleotide polymorphisms are being found in key candidate genes and are studied in familial or sporadic disease cohorts [33, 34] . Hereditary factors may contribute to the risk of NSIP. The role of surfactant has drawn increasing attention in interstitial lung disease [34] . Surfactant protein (SP)-A plays a role in the surfactant tension-lowering abilities of surfactant [34] . McCormack et al. [35] hypothesized that the alteration in the surfactant lipid composition changes its biophysical activity, diminishes lung compliance, and promotes lung fibrosis. They found reduced SP-A levels in BAL fluid [35] . Thomas 
Clinical presentation
Because the definition of NSIP was first based on the finding that the histopathologic pattern did not fit that of the classic patterns of other IIPs, histopathologic and clinical heterogeneity can be expected. To date, most clinical studies have started with pathology series in the diagnosis of NSIP. Thereafter, these data were related to clinical and imaging features. NSIP deserves to be individualized as a distinct, or possibly a series of distinct, clinicohistopathologic syndromes [37] .
In general, patients with NSIP experience slowly progressive dyspnea. Other common symptoms include nonproductive cough, fatigue, malaise, anorexia, and weight loss (see also Table 1 ). In some cases (low-grade) fever and connective tissue disease-related symptoms have been reported [38] . Clubbing was reported in 10% of the patients with NSIP, in none of the patients with bronchiolitis obliterans organizing pneumonia, and in 65% of the IPF cases in a study by Nagai et al. [38] . In line with this latter study, Cottin et al. [37] showed a decreased diffusion capacity in all studied cases (n = 12), a restrictive ventilatory defect in 92% of the cases, and evidence of a mild obstructive defect in 42% of the cases. Seven patients (58%) were hypoxic at rest. Furthermore, at exercise the arterial oxygen tension (PaO 2 ) decreased significantly by 0.5 kPa or more in 67% of the cases. Physical examination revealed the presence of inspiratory crackles in almost all patients (92%) and to a lesser extent squeaks (25%) [37] . Laboratory tests are nonspecific. An increase of the erythrocyte sedimentation rate and serum lactate dehydrogenase is found more frequently.
The [37] attempted to identify common features allowing NSIP to be considered as a distinct entity. The histopathologic lesions reported were temporally uniform. These latter authors concluded that temporal uniformity was the main feature differentiating NSIP from UIP. Other differences between these entities included the prominence of the interstitial inflammatory lesions in NSIP, with the absence of honeycombing [37,41•] .
The HRCT features were heterogeneous, including ground glass opacities (in 9 of 12 cases) and patchy alveolar consolidation (in 6 of 12 cases). In contrast, MacDonald et al. [39] reported that the accuracy of thinsection CT in identifying NSIP appeared to be considerably higher than previously reported in patients with a clinical presentation of IPF. Moreover, at CT, NSIP ( Fig. 2A, B) was characterized by more ground glass attenuation and a finer reticular pattern than was UIP (Fig. 2C) . Nevertheless, considerable overlap in thin-section CT patterns existed between NSIP and UIP [39] . In line with Katzenstein and Meyers [8], Hartman et al. [42] suggested that it is important to identify instances in which there is discordance between the histologic and radiologic findings and to recognize the sampling limitations of biopsy compared with HRCT.
It is impossible to differentiate NSIP from other IIPs using transbronchial lung biopsies. However, Watanabe et al. [43•] suggested that patients with IIP presenting as a cellular interstitial pneumonia on transbronchial lung biopsy, in the context of radiographic features that were not typical for UIP, could expect a beneficial effect from corticosteroids, thereby reducing the need for surgical biopsy in patients with this constellation of features.
Bronchoalveolar lavage
Provided its limitations are kept in mind, there appears to be a place for BAL in the evaluation of diffuse lung diseases. The pattern of inflammatory cells may be helpful in narrowing the differential diagnosis [44] . The lavage profile alone is nonspecific in IIP. However, the cellular BAL fluid profile in IPF appears to be quite different from the profile assessed from patients with disorders with similar clinical presentation (eg, sarcoidosis or hypersensitivity pneumonitis). Distinguishing IPF from NSIP using the pattern of inflammatory cells in BAL fluid is far more difficult. Patients with NSIP have a relative hypercellularity. A BAL fluid lymphocytosis with a predominance of a suppressor subset of T lymphocytes in BAL fluid is more suggestive of NSIP, cellular variant, than IPF [38] . If BAL is studied in a group of patients with the clinical features of IPF, lymphocytes are no more frequent than in IPF. The clinical value of BAL to stage or monitor interstitial lung disease is of limited value. Increases in the number of polymorphonuclear neutrophils or eosinophils have been associated with a worse prognosis, whereas a lymphocytosis in general has been noted to be associated with a better outcome and a greater responsiveness to corticosteroids.
Treatment
Only a few studies reported the effect of therapeutic interventions in NSIP [8, 38] . Katzenstein and Meyers [8] underscored the importance of distinguishing IPF with its histologic correlate UIP from other causes of IIP, especially NSIP. They reported that 45% of the patients with NSIP (n = 64) recovered completely, and an additional 42% remained at least stable or improved with corticosteroid treatment. Therefore, the differentiation between non-UIP and UIP among IIPs has become more and more important. In line with this, it is mandatory to have good criteria to distinguish NSIP from clinically similar IIPs, such as IPF, to predict a favorable outcome. Furthermore, without the establishment of an accurate diagnosis, it will be impossible to test new therapies that may improve the quality of life and establish a more favorable outcome. To date no data are available regarding the quality of life in NSIP. As in IPF [26] , although to a lesser extent, the severity of NSIP, the reduced life expectancy, and the sometimes disappointing response to therapy emphasize the importance of this issue. Because it is not always possible to obtain histopathologic specimens, the indications for the use of corticosteroids for patients with IIP including NSIP, unlikely to have UIP, have been determined by using clinical information, HRCT, BAL, and transbronchial lung biopsy information [43•].
Lone corticosteroid therapy
The first-line treatment for NSIP is, as for IPF, prednisolone 20 mg alternate days plus azathioprine 2.5 mg/kg to a maximum of 150 mg or cyclophosphamide 2 mg/kg to a maximum of 150 mg a day
reported a beneficial effect of corticosteroids in cases with NSIP presenting with cellular interstitial pneumonia in transbronchial lung biopsy. The dose of corticosteroids used varied from a daily dose of 30 to 160 mg with a mean dose of 60 mg daily in the NSIP group (n = 10) and a mean of 95 mg daily (range, 30 to 260mg) in the non-UIP group (n = 9). However, they have not compared the benefit of prednisone alone with the currently recommended first-line treatment. Moreover, the corticosteroid dosage regimen was not defined clearly. None of the included cases was treated with a comparable dose [43•]. So, the real benefit of corticosteroids should be investigated more thoroughly in a well-designed pro- spective study including a population with an appropriate sample size and homogeneity. In that the corticosteroid response to IPF is disappointing, a response to corticosteroids after 1 month of treatment points to a non-IPF form of IIP and predicts a better outcome [38] .
Combination corticosteroids and immunosuppressive therapy
In IPF some studies have been performed to evaluate the advantage of combined corticosteroids and immunosuppressive agents [5, 10] . Corticosteroids combined with azathioprine were shown to be safe and seemed more effective than corticosteroids alone [10]. Nagai et al. [38] reported that cyclophosphamide or azathioprine was used as an immunosuppressant whenever the initial response to corticosteroids was ineffective. However, the outcome of this approach was not quite clear. So, whether this combination is useful in selected NSIP cases needs future studies.
Other therapeutic directions
Reactive oxygen species released by inflammatory cells in the lung are involved in inflammation and cell In IPF, attempts have been made to find therapeutic agents that interfere with or modify the progression of the fibrotic lesions. Ziesche et al. [48] reported preliminary data reporting the benefit of interferon-␥ in patients with resistant IPF. This and other antifibrotic agents, including pirfenidone [49] , are potentially ready to be studied more extensively in clinical trials. Hopefully these efforts will provide new therapeutic strategies for NSIP as well, aimed at achieving better outcomes and improvement in patients' quality of life.
Adjunctive and other treatment modalities
As in IPF, it seems reasonable to immunize against Streptococcus pneumonia every 5 years, and we recommend influenza vaccination every year. Oxygen therapy might be required. NSIP patients might benefit from rehabilitation programs.
Conclusion
An understanding of the alveolar microenvironment in patients with IIP is crucial to the development of new, meaningful therapeutic interventions for this disease [15] . To demonstrate efficacy and quality-of-life improvement, well-designed, multicenter, prospective, randomized clinical trials including enough patients are mandatory.
